Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.
about
Capecitabine in the management of colorectal cancerNeoadjuvant chemoradiation therapy and pathological complete response in rectal cancerNeoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancerTP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial.Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS studyEvaluation of capecitabine and oxaliplatin administered prior to and then concomitant to radiotherapy in high risk locally advanced rectal cancer.Neoadjuvant chronomodulated capecitabine with radiotherapy in rectal cancer: a phase II brunch regimen study.Neoadjuvant therapy before surgical treatmentSystematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer.Therapeutic approaches in the management of locally advanced rectal cancer.The role of capecitabine in locally advanced rectal cancer treatment: an update.Peri-operative chemotherapy in the management of resectable colorectal cancer pulmonary metastases.Identification of a DNA methylation signature to predict disease-free survival in locally advanced rectal cancer.Phase II trial evaluating the feasibility of interdigitating folfox with chemoradiotherapy in locally advanced and metastatic rectal cancer.Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reductionShort course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study.Neoadjuvant-intensified treatment for rectal cancer: time to change?Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trialGender-specific acute organ toxicity during intensified preoperative radiochemotherapy for rectal cancer.Review of Neoadjuvant Chemotherapy Alone in Locally Advanced Rectal Cancer.Neoadjuvant treatment in rectal cancer: actual status.Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer.Current status of intensified neo-adjuvant systemic therapy in locally advanced rectal cancer.The current state of targeted agents in rectal cancer.MRI volumetry for prediction of tumour response to neoadjuvant chemotherapy followed by chemoradiotherapy in locally advanced rectal cancerTransrectal ultrasound and magnetic resonance imaging measurement of extramural tumor spread in rectal cancer.The value of image-guided intensity-modulated radiotherapy in challenging clinical settings.Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.Treatment of locally advanced rectal cancer: controversies and questions.Evaluation of treatment response and tissue necrosis as prognostic indicators following neoadjuvant chemoradiotherapy in rectal cancer patientsPretreatment high-resolution rectal MRI and treatment response to neoadjuvant chemoradiationExtramural depth of rectal cancer tumor invasion at thin-section MRI: predicting treatment response to neoadjuvant chemoradiation.A prospective feasibility study to evaluate neoadjuvant-synchronous S-1 with radiotherapy for locally advanced rectal cancer: A multicentre phase II trial.Selecting patients with locally advanced rectal cancer for neoadjuvant treatment strategies.Clinical factors of post-chemoradiotherapy as valuable indicators for pathological complete response in locally advanced rectal cancerPretreatment magnetic resonance imaging of regional lymph nodes with carcinoembryonic antigen in prediction of synchronous distant metastasis in patients with rectal cancer.Defining response to radiotherapy in rectal cancer using magnetic resonance imaging and histopathological scales.Phase II Study of Preoperative Capecitabine and Oxaliplatin-based Intensified Chemoradiotherapy With or Without Induction Chemotherapy in Patients With Locally Advanced Rectal Cancer and Synchronous Liver-limited Resectable Metastases.Surgical outcomes of post chemoradiotherapy unresectable locally advanced rectal cancers improve with interim chemotherapy, is FOLFIRINOX better than CAPOX?Rectal cancer radiotherapy: towards European consensus.
P2860
Q24633039-15E4144D-A8AF-425B-B5D9-CFD724EA3F06Q26796352-851136AC-70DC-4805-BDE7-47C0F85658B6Q27003878-2D91F6D1-A2A5-4E33-86E3-956CDB784FCCQ27853024-E5CF8A79-6C9B-412F-9A2A-44D7C26538C0Q33394804-272A7824-B187-4E6C-9624-F868E20EDC7EQ33411783-EA946082-539D-49E0-ABC7-938BB8AD2C7AQ33416945-C3376E5F-95AD-463E-AAD3-7982E4833AE8Q33697924-99EA7287-F82E-438C-B665-A796DCAD03FDQ34169310-526B12D7-89CF-4E9E-9D10-DDE528602191Q34234928-E59FAF0E-959C-4A4D-ADEC-A847656172B7Q34276823-EAFF52FA-B953-4290-B728-D0DA5443111CQ34360237-1BC85A23-76F0-46C7-A3B6-94ABAC65B2BCQ34483466-17320B81-0A2D-47F3-B354-E8E8B0C17142Q34499632-05A76D8B-6F3B-4416-A39E-42EE55D5C63BQ34577462-52899391-8EAB-4CC4-9D22-166331797867Q34633373-B189FD0D-C95A-4C85-AED5-5C5A84A1D1FDQ34743672-26AACAA5-4984-46BC-84C9-E514859CA96CQ35046474-CAAC55C7-99A0-4E9C-B15B-988AED4F83DCQ35584836-DE91D924-7BF6-4BAE-8157-2EDA345F56D9Q35680327-5C55E2BE-FCA8-47A6-B408-65E2CD9C3D53Q35687452-C2CF4B2D-B676-4D86-8014-76C309E11906Q35709494-7487338D-7E62-49A1-B9CF-1EB3E85A8FC8Q35987944-FCD20B35-043A-4B5C-A649-F9FE334830DFQ35996651-CE72CB3D-A43A-4C48-9845-F5EE1F4BBF9DQ36235746-64F932D1-5B5B-4C87-9E2B-FC38E66E8478Q36285755-60FF92AF-E77A-4E23-86A3-F8E20C7A43CDQ36294866-240F51A3-9824-4E71-9415-91746F231E82Q36348179-3CBCACAB-7895-431F-A149-45EEBB139B1EQ36351882-8F711EBF-86A4-42C9-A5F7-9CE2D3F7589AQ36461108-73FC0B11-B501-4AFB-92C9-68F0555D7A3BQ36537952-0285C083-4060-48E0-A970-6A37D58344C9Q36557565-8B836487-F28F-4077-9E31-8709A6E149A3Q36742214-C439C013-EFB6-4F7C-ACEC-58B44FA7FE28Q37038486-421ED098-3EC7-4FA7-812E-16FB0100F524Q37156190-030FEA66-A8DF-41F3-AF4F-513E60A45502Q37317210-6C9B823E-67B5-4D0C-A9A5-FEF0C4A86AAFQ37322482-ACCC525B-DA92-44DC-B2F0-C4EC7AD6DAAAQ37432618-43B012E9-6246-477F-BCA5-48AD5032725AQ37525306-0BF8F461-594E-437E-ADF3-E6A23DB36662Q37789029-3783306A-273B-421C-966F-15DECB42FFB5
P2860
Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Neoadjuvant capecitabine and o ...... ectal cancer: a phase 2 trial.
@en
Neoadjuvant capecitabine and o ...... ectal cancer: a phase 2 trial.
@nl
type
label
Neoadjuvant capecitabine and o ...... ectal cancer: a phase 2 trial.
@en
Neoadjuvant capecitabine and o ...... ectal cancer: a phase 2 trial.
@nl
prefLabel
Neoadjuvant capecitabine and o ...... ectal cancer: a phase 2 trial.
@en
Neoadjuvant capecitabine and o ...... ectal cancer: a phase 2 trial.
@nl
P2093
P50
P1433
P1476
Neoadjuvant capecitabine and o ...... ectal cancer: a phase 2 trial.
@en
P2093
Alison Massey
Diana Tait
Jacqui R Oates
Niall C Tebbutt
Yolanda Barbachano
Yu Jo Chua
P304
P356
10.1016/S1470-2045(09)70381-X
P577
2010-01-25T00:00:00Z